Tomomi Takei

Pre-CAR-HEMATOTOX at Leukapheresis Predicts Delayed Platelet Recovery After Idecabtagene Vicleucel in Multiple Myeloma

Taku Kikuchi, Moe Nomura‐Yogo, Ukyo Kondo, So SUGITA et autres

jp (code pays fourni par la source)

Real‐world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single‐centre experience

Taku Kikuchi, Ukyo Kondo, So SUGITA, Miyu Watanabe et autres

jp (code pays fourni par la source)

Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre‐BCMA Era: A Prospective, Single‐Centre Study

Kota Sato, Kenshi Suzuki, So SUGITA, Ukyo Kondo et autres

ABSTRACT Objectives Minimal/measurable residual disease (MRD) negativity in multiple myeloma (MM) is associated with favourable outcomes; nonetheless, evidence supporting treatment discontinuation remains limited. We evaluated the feasibility of discontinuing antimyeloma therapy in patients with MRD negativity. Methods We analysed 41 patients who …

jp (code pays fourni par la source)

Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma

Taku Kikuchi, Ukyo Kondo, So SUGITA, Miyu Watanabe et autres

jp (code pays fourni par la source)

Prognostic significance of cardiac biomarkers in patients with AL amyloidosis treated with a daratumumab-based regimen

Taku Kikuchi, U Kondo, So SUGITA, Miyu Watanabe et autres

Daratumumab-based therapy has improved overall survival in patients with AL amyloidosis; however, the incidence of serious adverse events increases with advancing cardiac stage, and the European 20...

jp (code pays fourni par la source)

Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?

Taku Kikuchi, Ukyo Kondo, So SUGITA, Miyu Watanabe et autres

Chimeric antigen receptor T-cell (CAR-T) therapy is an effective treatment modality for patients with relapsed or refractory multiple myeloma following triple-class exposure.[1][2][3][4] Idecabtagene vicleucel (ide-cel), which is a CAR-T therapy targeting B-cell maturation antigen, 1 demonstrates superior outcomes compared to that of …

jp (code pays fourni par la source)

Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies

Taku Kikuchi, Yuki Oda, Ukyo Kondo, Nobuhiro Tsukada et autres

To retrospectively analyze whether the second revision of the international staging system (R2-ISS) influenced prognosis at treatment initiation in patients with multiple myeloma (MM) receiving anti-CD38 antibody-based triplet treatments. High-risk chromosomal abnormalities were examined from diagnosis to treatment initiation and considered positive …

jp (code pays fourni par la source)

Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma

Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Moe Nomura‐Yogo et autres

INTRODUCTION: Some treatments are associated with cytomegalovirus (CMV) reactivation (CMVRA) in patients with multiple myeloma (MM). However, no reports exist on the association between elotuzumab and CMVRA. Therefore, we assessed the incidence of CMVRA in patients with MM who received elotuzumab therapy. …

jp (code pays fourni par la source)

[Retrospective analysis of allogeneic hematopoietic stem cell transplantation for multiple myeloma after myeloablative conditioning with 8 Gy of total body irradiation].

Nobuhiro Tsukada, Moe Nomura‐Yogo, Kodai Kunisada, Yuki Oda et autres

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a curative treatment option for multiple myeloma (MM), but few patients are eligible due to its high risk of treatment-related toxicity and relapse. Here, we report the feasibility and efficacy of allo-SCT after myeloablative conditioning …

jp (code pays fourni par la source)